| Ryan Alan Williamson, MD | |
|
200 Hawthorne Ln, Charlotte, NC 28204-2515 | |
| (704) 384-9437 | |
| Not Available |
| Full Name | Ryan Alan Williamson |
|---|---|
| Gender | Male |
| Speciality | Neurology |
| Experience | 10 Years |
| Location | 200 Hawthorne Ln, Charlotte, North Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003234204 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Novant Health Presbyterian Medical Center | Charlotte, NC | Hospital |
| Cookeville Regional Medical Center | Cookeville, TN | Hospital |
| Novant Health Rowan Medical Center | Salisbury, NC | Hospital |
| Novant Health Huntersville Medical Center | Huntersville, NC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Novant Medical Group Inc | 1153234893 | 1996 |
| Cookeville Regional Medical Center | 7810805736 | 28 |
News Archive
InterMune, Inc. today announced that the company's Marketing Authorization Application (MAA), submitted on March 2 seeking approval of pirfenidone for the treatment of idiopathic pulmonary fibrosis (IPF) in adults, was validated by the European Medicines Agency (EMA). Validation of the MAA by the EMA indicates that the application is complete and that the review process will begin on March 24. The proposed trade name for pirfenidone in both the United States and Europe is Esbriet®.
Simulated Environment Concepts, the manufacturer and developer of medical, aesthetic, weight loss, wellness, and slimming equipment, announced today that the Company has made the first delivery of the SpaCapsule to Elements Diet and Fitness (Elements), a women's health and fitness center, in accordance with the co-branding preferred vendor's agreement executed between the two companies earlier this year.
Black Medicare beneficiaries "fare worse" than white beneficiaries "even when they belong to the same health plan," an indication that health care disparities "cannot be attributed to individual, inferior doctors," according to a study published on Wednesday in the Journal of the American Medical Association, the Boston Globe reports.
Alectos Therapeutics Inc. today announced a research collaboration with Merck, headquartered in Whitehouse Station, N.J., to identify and develop compounds that modulate O-linked N-acetylglucosaminidase (O-GlcNAcase) an enzyme that is believed to be involved in the development of Alzheimer's disease and potentially other disorders. The agreement provides Merck with a worldwide, exclusive license to research, develop and commercialize compounds that modulate this target.
› Verified 8 days ago
| Entity Name | Novant Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366409492 PECOS PAC ID: 1153234893 Enrollment ID: O20031121000692 |
News Archive
InterMune, Inc. today announced that the company's Marketing Authorization Application (MAA), submitted on March 2 seeking approval of pirfenidone for the treatment of idiopathic pulmonary fibrosis (IPF) in adults, was validated by the European Medicines Agency (EMA). Validation of the MAA by the EMA indicates that the application is complete and that the review process will begin on March 24. The proposed trade name for pirfenidone in both the United States and Europe is Esbriet®.
Simulated Environment Concepts, the manufacturer and developer of medical, aesthetic, weight loss, wellness, and slimming equipment, announced today that the Company has made the first delivery of the SpaCapsule to Elements Diet and Fitness (Elements), a women's health and fitness center, in accordance with the co-branding preferred vendor's agreement executed between the two companies earlier this year.
Black Medicare beneficiaries "fare worse" than white beneficiaries "even when they belong to the same health plan," an indication that health care disparities "cannot be attributed to individual, inferior doctors," according to a study published on Wednesday in the Journal of the American Medical Association, the Boston Globe reports.
Alectos Therapeutics Inc. today announced a research collaboration with Merck, headquartered in Whitehouse Station, N.J., to identify and develop compounds that modulate O-linked N-acetylglucosaminidase (O-GlcNAcase) an enzyme that is believed to be involved in the development of Alzheimer's disease and potentially other disorders. The agreement provides Merck with a worldwide, exclusive license to research, develop and commercialize compounds that modulate this target.
› Verified 8 days ago
| Entity Name | Forsyth Memorial Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1104548874 PECOS PAC ID: 9537071790 Enrollment ID: O20040405001702 |
News Archive
InterMune, Inc. today announced that the company's Marketing Authorization Application (MAA), submitted on March 2 seeking approval of pirfenidone for the treatment of idiopathic pulmonary fibrosis (IPF) in adults, was validated by the European Medicines Agency (EMA). Validation of the MAA by the EMA indicates that the application is complete and that the review process will begin on March 24. The proposed trade name for pirfenidone in both the United States and Europe is Esbriet®.
Simulated Environment Concepts, the manufacturer and developer of medical, aesthetic, weight loss, wellness, and slimming equipment, announced today that the Company has made the first delivery of the SpaCapsule to Elements Diet and Fitness (Elements), a women's health and fitness center, in accordance with the co-branding preferred vendor's agreement executed between the two companies earlier this year.
Black Medicare beneficiaries "fare worse" than white beneficiaries "even when they belong to the same health plan," an indication that health care disparities "cannot be attributed to individual, inferior doctors," according to a study published on Wednesday in the Journal of the American Medical Association, the Boston Globe reports.
Alectos Therapeutics Inc. today announced a research collaboration with Merck, headquartered in Whitehouse Station, N.J., to identify and develop compounds that modulate O-linked N-acetylglucosaminidase (O-GlcNAcase) an enzyme that is believed to be involved in the development of Alzheimer's disease and potentially other disorders. The agreement provides Merck with a worldwide, exclusive license to research, develop and commercialize compounds that modulate this target.
› Verified 8 days ago
| Entity Name | Sentara Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1265485270 PECOS PAC ID: 8921903923 Enrollment ID: O20070626000554 |
News Archive
InterMune, Inc. today announced that the company's Marketing Authorization Application (MAA), submitted on March 2 seeking approval of pirfenidone for the treatment of idiopathic pulmonary fibrosis (IPF) in adults, was validated by the European Medicines Agency (EMA). Validation of the MAA by the EMA indicates that the application is complete and that the review process will begin on March 24. The proposed trade name for pirfenidone in both the United States and Europe is Esbriet®.
Simulated Environment Concepts, the manufacturer and developer of medical, aesthetic, weight loss, wellness, and slimming equipment, announced today that the Company has made the first delivery of the SpaCapsule to Elements Diet and Fitness (Elements), a women's health and fitness center, in accordance with the co-branding preferred vendor's agreement executed between the two companies earlier this year.
Black Medicare beneficiaries "fare worse" than white beneficiaries "even when they belong to the same health plan," an indication that health care disparities "cannot be attributed to individual, inferior doctors," according to a study published on Wednesday in the Journal of the American Medical Association, the Boston Globe reports.
Alectos Therapeutics Inc. today announced a research collaboration with Merck, headquartered in Whitehouse Station, N.J., to identify and develop compounds that modulate O-linked N-acetylglucosaminidase (O-GlcNAcase) an enzyme that is believed to be involved in the development of Alzheimer's disease and potentially other disorders. The agreement provides Merck with a worldwide, exclusive license to research, develop and commercialize compounds that modulate this target.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ryan Alan Williamson, MD 100 Brewster Blvd, Camp Lejeune, NC 28547-2575 Ph: (910) 450-4300 | Ryan Alan Williamson, MD 200 Hawthorne Ln, Charlotte, NC 28204-2515 Ph: (704) 384-9437 |
News Archive
InterMune, Inc. today announced that the company's Marketing Authorization Application (MAA), submitted on March 2 seeking approval of pirfenidone for the treatment of idiopathic pulmonary fibrosis (IPF) in adults, was validated by the European Medicines Agency (EMA). Validation of the MAA by the EMA indicates that the application is complete and that the review process will begin on March 24. The proposed trade name for pirfenidone in both the United States and Europe is Esbriet®.
Simulated Environment Concepts, the manufacturer and developer of medical, aesthetic, weight loss, wellness, and slimming equipment, announced today that the Company has made the first delivery of the SpaCapsule to Elements Diet and Fitness (Elements), a women's health and fitness center, in accordance with the co-branding preferred vendor's agreement executed between the two companies earlier this year.
Black Medicare beneficiaries "fare worse" than white beneficiaries "even when they belong to the same health plan," an indication that health care disparities "cannot be attributed to individual, inferior doctors," according to a study published on Wednesday in the Journal of the American Medical Association, the Boston Globe reports.
Alectos Therapeutics Inc. today announced a research collaboration with Merck, headquartered in Whitehouse Station, N.J., to identify and develop compounds that modulate O-linked N-acetylglucosaminidase (O-GlcNAcase) an enzyme that is believed to be involved in the development of Alzheimer's disease and potentially other disorders. The agreement provides Merck with a worldwide, exclusive license to research, develop and commercialize compounds that modulate this target.
› Verified 8 days ago
Soong Hyun Lee, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: Behavioral Health Center Cmc Randolph, 501 Billingsley Road, Charlotte, NC 28211 Phone: 704-358-2700 Fax: 704-358-2716 | |
Dr. Richard David Jacobson, MD, PHD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 4228 Brookfield Dr, Charlotte, NC 28210 Phone: 615-345-5400 | |
Stephanie Francis Newby, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 501 Billingsley Rd, Ste B, Charlotte, NC 28211 Phone: 704-444-2400 | |
Dr. T Hemanth Rao, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 2607 E 7th St Ste 200, Charlotte, NC 28204 Phone: 704-449-6064 Fax: 704-731-0936 | |
Boris Maximovich Kiselev, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 501 Billingsley Rd, Ste B, Charlotte, NC 28211 Phone: 704-444-2400 | |
Dr. Sumul Modi, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 5500 Executive Center Dr Ste 206, Charlotte, NC 28212 Phone: 984-777-9940 Fax: 877-794-5929 |